Financial Highlights and Market Update
USA, Europe, Canada and Australia (Core Markets)
☐ Revenue:
We delivered a strong performance with growth in existing
products including Micafungin, Enoxaparin, Heparin,
Dexmedetomidine among
and
among others
new prod-
uct launches. It was also an important milestone to launch
our first set of penem products for the US market.
■ New launches(2);
Q1 FY21: 17 Product SKUS (12 molecules)
US filings update:
As of June 30, 2021, we along with our partners had 286
ANDA filings in the United States, of which 239 were
approved and 47 pending approval.
ANDA Filed
ANDA Approved
DMFS Filed
Q1 FY22
2
6(3)
LO
6%
USA
Q1 FY22: Rs. 7,042 Mn
YoY Growth: 16%
Core Markets (1)
Revenue Contribution
Q1
FY21
63%
7%
Q1
FY22
54%
7
Note: ANDA count includes technology transfer ANDAS
Europe, Canada and Australia
(1) Core markets includes USA, Europe, Canada and Australia (2) Includes products where launch quantity is dispatched to our partners (3) Received final approval for one product which was earlier tentatively approved
GLANDView entire presentation